Full text
Earnings transcript
Read the complete earnings call transcript.
PHR
Phreesia, Inc.
$9.29
-0.05
(-0.54%)
| Exchange: | NYSE |
| Market Cap: | 574.232M |
| Shares Outstanding: | 1.539M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Information Services | |||||
| CEO: | Chaim Indig | |||||
| Full Time Employees: | 2082 | |||||
| Address: |
| |||||
| Website: | https://www.phreesia.com |
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 356,299 | 419,813 | 480,591 |
| Gross Profit | 232,288 | 284,879 | 326,468 |
| EBITDA | -102,945 | -25,578 | 29,466 |
| Operating Income | -136,479 | -58,097 | -6,612 |
| Net Income | -136,885 | -58,527 | 2,306 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 370,326 | 388,415 | 663,790 |
| Total Liabilities | 118,877 | 123,607 | 326,583 |
| Total Stockholders Equity | 251,449 | 264,808 | 337,207 |
| Total Debt | 11,983 | 17,803 | 93,224 |
| Cash and Cash Equivalents | 87,520 | 84,220 | 73,830 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | -32,378 | 32,381 | 78,814 |
| Capital Expenditure | -25,097 | -24,089 | -11,101 |
| Free Cash Flow | -57,475 | 8,292 | 67,713 |
| Net Income | -136,885 | -58,527 | 2,306 |
| Net Change in Cash | -89,163 | -3,300 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 539,700.343 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 568,520.487 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 553,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 262,231.792 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 276,235.040 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 268,693.883 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 58,976.663 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 63,101.125 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 60,879.930 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 337,693.021 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 355,725.920 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 346,014.679 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.990 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 1.030 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.960 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Growth: Phreesia reported Q4 Fiscal 2025 revenue of $109.7 million, reflecting a 15% year-over-year increase as highlighted in the earnings call transcript. This growth indicates strong demand for its healthcare technology solutions and consistent business expansion.
- Operational Efficiency: The earnings call summary emphasizes improvements in operational efficiency, contributing to better margins. Key metrics such as gross profit margin (TTM) and net profit margin (TTM) likely support this trend, showcasing the company’s ability to manage costs effectively.
- Innovative Product Offerings: The company continues to invest in product development, as noted in the earnings call, positioning Phreesia as a competitive player in the healthcare technology sector. This focus on innovation aligns with industry trends toward digital transformation.
- Strong Market Position: Phreesia’s performance metrics (e.g., perf1y, perf5y) compared to industry averages (industry_perf1y, industry_perf5y) suggest a robust standing within the healthcare IT industry, supported by a growing market cap and consistent revenue streams across product segments.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about PHR valuation
Is Phreesia, Inc. (PHR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Phreesia, Inc. (PHR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PHR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PHR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PHR’s P/E ratio?
You can see PHR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PHR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PHR a good long-term investment?
Whether PHR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PHR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.54
Trading Metrics:
| Open: | 9.22 | Previous Close: | 9.34 | |
| Day Low: | 9.12 | Day High: | 9.64 | |
| Year Low: | 7.77 | Year High: | 32.76 | |
| Price Avg 50: | 9.3 | Price Avg 200: | 16.56 | |
| Volume: | 843042 | Average Volume: | 2.218M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freePHR full analysis
Welcome to MARKETSNAP’s SWOT analysis for Phreesia, a player in the healthcare technology space that might not be on everyone’s radar just yet. If you’re a long-term investor looking to diversify into innovative sectors, stick around as we break down what makes Phreesia tick, where it’s shining, and where it might trip up. Let’s dive into a comprehensive look at this company, blending recent developments with hard financial data to see if it’s a worthy addition to your portfolio. First…
